Copyright Reports & Markets. All rights reserved.

Global Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Glioblastoma Multiforme Treatment Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Bevacizumab (Avastin)
    • 1.4.3 Carmustine (BiCNU)
    • 1.4.4 Temozolomide (Temodar and Temodal and Temcad)
  • 1.5 Market by Application
    • 1.5.1 Global Glioblastoma Multiforme Treatment Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Glioblastoma Multiforme Treatment Market Perspective (2015-2026)
  • 2.2 Global Glioblastoma Multiforme Treatment Growth Trends by Regions
    • 2.2.1 Glioblastoma Multiforme Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Glioblastoma Multiforme Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Glioblastoma Multiforme Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Glioblastoma Multiforme Treatment Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Glioblastoma Multiforme Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Glioblastoma Multiforme Treatment Players by Market Size
    • 3.1.1 Global Top Glioblastoma Multiforme Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Glioblastoma Multiforme Treatment Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Glioblastoma Multiforme Treatment Market Concentration Ratio
    • 3.2.1 Global Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Treatment Revenue in 2019
  • 3.3 Glioblastoma Multiforme Treatment Key Players Head office and Area Served
  • 3.4 Key Players Glioblastoma Multiforme Treatment Product Solution and Service
  • 3.5 Date of Enter into Glioblastoma Multiforme Treatment Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Glioblastoma Multiforme Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)
  • 5.2 Global Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 6.2 Glioblastoma Multiforme Treatment Key Players in North America (2019-2020)
  • 6.3 North America Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 6.4 North America Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 7.2 Glioblastoma Multiforme Treatment Key Players in Europe (2019-2020)
  • 7.3 Europe Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 7.4 Europe Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

8 China

  • 8.1 China Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 8.2 Glioblastoma Multiforme Treatment Key Players in China (2019-2020)
  • 8.3 China Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 8.4 China Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 9.2 Glioblastoma Multiforme Treatment Key Players in Japan (2019-2020)
  • 9.3 Japan Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 9.4 Japan Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 10.2 Glioblastoma Multiforme Treatment Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

11 India

  • 11.1 India Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 11.2 Glioblastoma Multiforme Treatment Key Players in India (2019-2020)
  • 11.3 India Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 11.4 India Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Glioblastoma Multiforme Treatment Market Size (2015-2020)
  • 12.2 Glioblastoma Multiforme Treatment Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Glioblastoma Multiforme Treatment Market Size by Type (2015-2020)
  • 12.4 Central & South America Glioblastoma Multiforme Treatment Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 AbbVie, Inc
    • 13.1.1 AbbVie, Inc Company Details
    • 13.1.2 AbbVie, Inc Business Overview
    • 13.1.3 AbbVie, Inc Glioblastoma Multiforme Treatment Introduction
    • 13.1.4 AbbVie, Inc Revenue in Glioblastoma Multiforme Treatment Business (2015-2020))
    • 13.1.5 AbbVie, Inc Recent Development
  • 13.2 Activartis GmbH
    • 13.2.1 Activartis GmbH Company Details
    • 13.2.2 Activartis GmbH Business Overview
    • 13.2.3 Activartis GmbH Glioblastoma Multiforme Treatment Introduction
    • 13.2.4 Activartis GmbH Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.2.5 Activartis GmbH Recent Development
  • 13.3 Agenus Inc
    • 13.3.1 Agenus Inc Company Details
    • 13.3.2 Agenus Inc Business Overview
    • 13.3.3 Agenus Inc Glioblastoma Multiforme Treatment Introduction
    • 13.3.4 Agenus Inc Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.3.5 Agenus Inc Recent Development
  • 13.4 Arog Pharmaceuticals, Inc
    • 13.4.1 Arog Pharmaceuticals, Inc Company Details
    • 13.4.2 Arog Pharmaceuticals, Inc Business Overview
    • 13.4.3 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Introduction
    • 13.4.4 Arog Pharmaceuticals, Inc Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.4.5 Arog Pharmaceuticals, Inc Recent Development
  • 13.5 Bristol-Myers Squibb Company
    • 13.5.1 Bristol-Myers Squibb Company Company Details
    • 13.5.2 Bristol-Myers Squibb Company Business Overview
    • 13.5.3 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Introduction
    • 13.5.4 Bristol-Myers Squibb Company Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.5.5 Bristol-Myers Squibb Company Recent Development
  • 13.6 Cavion LLC
    • 13.6.1 Cavion LLC Company Details
    • 13.6.2 Cavion LLC Business Overview
    • 13.6.3 Cavion LLC Glioblastoma Multiforme Treatment Introduction
    • 13.6.4 Cavion LLC Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.6.5 Cavion LLC Recent Development
  • 13.7 Celldex Therapeutics Inc
    • 13.7.1 Celldex Therapeutics Inc Company Details
    • 13.7.2 Celldex Therapeutics Inc Business Overview
    • 13.7.3 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Introduction
    • 13.7.4 Celldex Therapeutics Inc Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.7.5 Celldex Therapeutics Inc Recent Development
  • 13.8 Cortice Biosciences
    • 13.8.1 Cortice Biosciences Company Details
    • 13.8.2 Cortice Biosciences Business Overview
    • 13.8.3 Cortice Biosciences Glioblastoma Multiforme Treatment Introduction
    • 13.8.4 Cortice Biosciences Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.8.5 Cortice Biosciences Recent Development
  • 13.9 Exelixis Inc
    • 13.9.1 Exelixis Inc Company Details
    • 13.9.2 Exelixis Inc Business Overview
    • 13.9.3 Exelixis Inc Glioblastoma Multiforme Treatment Introduction
    • 13.9.4 Exelixis Inc Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.9.5 Exelixis Inc Recent Development
  • 13.10 F. Hoffmann-La Roche Ltd.
    • 13.10.1 F. Hoffmann-La Roche Ltd. Company Details
    • 13.10.2 F. Hoffmann-La Roche Ltd. Business Overview
    • 13.10.3 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Introduction
    • 13.10.4 F. Hoffmann-La Roche Ltd. Revenue in Glioblastoma Multiforme Treatment Business (2015-2020)
    • 13.10.5 F. Hoffmann-La Roche Ltd. Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Glioblastoma Multiforme Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Glioblastoma Multiforme Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    AbbVie, Inc
    Activartis GmbH
    Agenus Inc
    Arog Pharmaceuticals, Inc
    Bristol-Myers Squibb Company
    Cavion LLC
    Celldex Therapeutics Inc
    Cortice Biosciences
    Exelixis Inc
    F. Hoffmann-La Roche Ltd.

    Market segment by Type, the product can be split into
    Bevacizumab (Avastin)
    Carmustine (BiCNU)
    Temozolomide (Temodar and Temodal and Temcad)
    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now